Go to content
${facet.Name} (${facet.TotalResults})
${item.Icon}
${ item.ShortDescription }
${ item.SearchLabel?.ViewModel?.Label }
See all results
${facet.Name} (${facet.TotalResults})
${item.Icon}
${ item.ShortDescription }
${ item.SearchLabel?.ViewModel?.Label }
See all results

Biography

Alan Au
Legal Profile Alan Au - no background

Alan Au

Partner | Hong Kong
+852 5806 7847 alan.au@harneys.com
Biography

Alan Au is a partner in our Corporate team based in our Hong Kong office. He advises PRC and international clients on a broad range of corporate transactions involving privatisations, initial public offerings, mergers and acquisitions, private and public equity and debt offering, SPAC and De-SPAC transactions, pre-IPO financing, joint ventures and share option and award schemes. Alan has a strong science and pharmaceutical background and has extensive experience in handling biotech companies’ corporate transactions and IPOs. His major clients include bulge bracket banks, PRC and international law firms, listed companies and private equi ...

Alan Au is a partner in our Corporate team based in our Hong Kong office. He advises PRC and international clients on a broad range of corporate transactions involving privatisations, initial public offerings, mergers and acquisitions, private and public equity and debt offering, SPAC and De-SPAC transactions, pre-IPO financing, joint ventures and share option and award schemes.

Alan has a strong science and pharmaceutical background and has extensive experience in handling biotech companies’ corporate transactions and IPOs. His major clients include bulge bracket banks, PRC and international law firms, listed companies and private equity institutions.

Prior to joining us, Alan was a senior corporate lawyer at Ogier. During his legal career, he has also worked at Fangda Partners, Shearman & Sterling, Bird & Bird, Sidley Austin and Robertsons. Before qualifying as a lawyer in 2012, Alan was a medical specialist at GlaxoSmithKline and Stiefel Laboratories.

Alan is fluent in Mandarin, English and Cantonese.

${ !hiddenTextVisible ?"Read more": " Show less"}
Recommendations

Alan is recognised as a rising star.

Alan is recognised as a rising star.

Alan is hailed for ground-breaking cases that defy precedents.

${ !hiddenTextVisible ?"Read more": " Show less"}

Capital markets

Advising iOThree Limited on its proposed listing on NASDAQ.

Advising AAG Energy Holdings Ltd on its privatisation by way of a scheme of arrangement and delisting from the Hong Kong Stock Exchange.

Advising Kazakh Steel on its dual primary listing on the Hong Kong Stock Exchange and the Astana International Exchange Ltd.

Advising JW (Cayman) Therapeutics Co., Ltd on its listing on the Hong Kong Stock Exchange.
Advising Goldman Sachs (Asia) L.L.C., CLSA Limited and UBS AG Hong Kong Branch on Hua Medicine’s listing on the Hong Kong Stock Exchange.

Advising Merrill Lynch (Asia Pacific) Limited, Goldman Sachs (Asia) L.L.C., CLSA Limited. and Haitong International Securities Company Limited on Frontage Holdings Corporation’s listing on the Hong Kong Stock Exchange.

Advising Merrill Lynch (Asia Pacific) Limited, Goldman Sachs (Asia) L.L.C. and CLSA Limited on Koolearn Technology Holding Limited’s listing on the Hong Kong Stock Exchange.

Advising Weiye Holdings Limited on its voluntary delisting of the shares from the Official List of the Mainboard of the Singapore Exchange Securities Trading Limited while remain listed on the Hong Kong Stock Exchange.

Advising Titan Financial Services Limited on the listing of Guan Chao Holdings Limited on the Hong Kong Stock Exchange.

Advising AL Group Limited on its listing on the Growth Enterprise Market of the Hong Kong Stock Exchange.

Advising Worldgate Global Logistics Limited on its listing on the Hong Kong Stock Exchange.

Advising LC Group Holdings Limited on its listing on the Hong Kong Stock Exchange.

Advising Baguio Green Holdings Limited on its listing on the Hong Kong Stock Exchange.

Advising CCBI on the listing of Major Holdings Limited on the Growth Enterprise Market of the Hong Kong Stock Exchange.

Advising PPS International (Holdings) Limited on its listing on the Hong Kong Stock Exchange.

Privatisations, mergers & acquisitions and private equity

Advising APG relating to the US$3.16 billion going-private of Chindata (named as “Private Equity Deal of the Year” at the 2024 IFLR Asia-Pacific Awards).

Advising an investor consortium including DCP Capital, Ocean Link and Rick Yan in the US$4.3 billion privatisation of 51job Inc. from NASDAQ (named as “Loan Deal of the Year” at the 2023 IFLR Asia-Pacific Awards).

Advising an investor consortium including New Frontier Public Holding Ltd, Vivo Capital Fund IX (Cayman), LP Fosun Industrial Co Limited, the private equity business within Goldman Sachs Asset Management, certain affiliates of Warburg Pincus LLC and other investors in the US$1.58 billion privatisation of New Frontier Health Corporation from the New York Stock Exchange (named as “Deals of the Year 2022” in the China Business Law Journal).

Advising Provident Acquisition Corp. in connection with its US$1.02 billion De-SPAC business combination with Perfect Corp.

Advising AAG Energy Holdings Limited on its US$347 million its privatisation by way of a Cayman scheme of arrangement and delisting from the Hong Kong Stock Exchange.

Advising Yoov Group Holding Limited on its proposed US$250 million reverse merger with Aptorum Group and listing on NASDAQ and the existing business of Aptorum Group be spun off.

Advising Xiezhong International Holdings Limited on its privatisation by way of a Cayman scheme of arrangement and delisting from the Hong Kong Stock Exchange.

Advising Provident Acquisition Corp. in connection with its business combination with Perfect Corp. Provident Acquisition is a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, share exchange, asset acquisition or other similar business combination with one or more businesses or entities and is sponsored by Provident Capital.

Advising ZMAY Holdings Limited, a company listed on the Hong Kong Stock Exchange, in the acquisition of a group of companies which held stem cell technology licenses.

Advising Ascent Capital Advisors Limited on its US$5.75 million equity financing to Dazzling Investment Holdings Limited.

Advising an investor consortium including New Frontier Public Holding Ltd, Vivo Capital Fund IX (Cayman), LP Fosun Industrial Co Limited, the private equity business within Goldman Sachs Asset Management, certain affiliates of Warburg Pincus LLC and other investors in the privatisation of New Frontier Health Corporation from the New York Stock Exchange.

Advising an investor consortium including DCP Capital, Ocean Link and Rick Yan in the privatisation of 51job Inc. from NASDAQ.

Advising Xiezhong International Holdings Limited on its privatisation by way of a scheme of arrangement and delisting from the Hong Kong Stock Exchange.

Advising the offeror, Mystery Idea Limited, in relation to the mandatory conditional cash offer of Forefront Group Limited, a company listed on the Hong Kong Stock Exchange.

Advising Victory Group Limited for the resumption of trading which was under its last stage of de-listing procedure in Hong Kong.

British Virgin Islands
2023

England and Wales
2022

Hong Kong (not practising)
2012

University of Hong Kong (LLM)
2013

University of Hong Kong (PCLL)
2010

University of London (LLB)
2009

University of British Columbia (BSc)
2005